Exosomes in Cancer Therapy

外泌体在癌症治疗中的应用

• 批准号: 9897907
• 负责人: RAGHU KALLURI
• 金额: $ 4.02万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-12-27 至 2021-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9897907
• 关键词: Apoptosis; Applications Grants; Biological Assay; Biology; Blood Circulation; Brain; CD47 gene; Cell Proliferation; Cells; Clinic; Clinical; Codon Nucleotides; Complement; Coupled; Cultured Cells; DNA; Data; Disease; Eating; Electroporation; Endopeptidase K; Engineering; Exhibits; Extracellular Protein; Fibroblasts; Frequencies; Future; Genetic; Genetic study; Genetically Engineered Mouse; Glycine; Half-Life; Human; ITGAM gene; Image; Impairment; Integrins; Investigation; KRAS2 gene; Liposomes; Liver; Lung; Malignant Neoplasms; Malignant neoplasm of pancreas; Mediating; Mediator of activation protein; Molecular; Mus; Mutation; Oncogenic; Pancreas; Pancreatic Ductal Adenocarcinoma; Pathogenesis; Pathway interactions; Patients; Performance; Phagocytes; Pharmaceutical Preparations; Pharmacology; Physiological; Play; Process; Proteins; Proteomics; RNA; RNA Interference; Research; Role; Route; Signal Transduction; Small Interfering RNA; Survival Rate; System; Techniques; Tertiary Protein Structure; Testing; Therapeutic; Tissues; Trypsin; Western Blotting; Xenograft procedure; base; cancer therapy; design; dosage; effective therapy; exosome; experimental study; extracellular vesicles; imaging modality; improved; insight; knowledge translation; macrophage; monocyte; mouse model; nanoparticle; neutralizing antibody; novel strategies; novel therapeutics; off-label use; outcome forecast; pancreatic cancer cells; pancreatic cancer model; pancreatic neoplasm; penis foreskin; pre-clinical; preclinical study; programs; small hairpin RNA; standard of care; therapeutic evaluation; tumor; tumor progression

Project Summary Pancreatic Ductal Adenocarcinoma (PDAC) has a dismal prognosis with a median survival of about 6 months for patients with metastatic disease despite the use of current treatments. Therefore, PDAC is in urgent need of effective therapies. About 80% of PDAC patients exhibit mutation in KRAS, with substitution of a glycine residue at codon 12, such as KRASG12D, observed in high frequency. Many studies in mice unequivocally show that direct inhibition oncogenic KRAS significantly suppresses tumor progression. Despite such compelling evidence for the functional role of oncogenic KRAS in the PDAC pathogenesis, direct targeting of oncogenic KRAS has been elusive and it has often been dubbed as ‘undruggable’. In this grant application, we propose to explore a novel approach to target oncogenic KRAS using physiological nanoparticles known as exosomes. Exosomes are 40-150 nm extracellular vesicles (EVs) that contain DNA, RNA and proteins, and can deliver their contents efficiently into cells they fuse with and/or enter. Exploiting this unique feature of exosomes, our research team proposes in this grant application to test the central hypothesis that ‘exosomes can be engineered to deliver RNA interference (RNAi) molecules to target KRASG12D in pancreatic cancer’. Successful completion of the proposed studies will determine whether exosomes exhibit a superior ability to deliver RNAi molecules for the treatment of pancreatic cancer when compared to liposomes. Additionally, after such increased ability is investigated using multiple experimental systems, the proposal will further identify mechanism/s associated with the enhanced efficacy of exosomes in the delivery of RNAi molecules. Collectively, the proposal is designed to enable in-depth pre-clinical studies coupled with an investigation into the unique mechanism of action of exosomes to potentially facilitate future therapeutic testing in patients with PDAC.

项目摘要 胰腺导管腺癌（PDAC）预后差，中位生存期约为6个月 对于转移性疾病的患者，尽管使用当前的治疗。因此，PDAC是迫切需要的 有效的治疗方法。约80%的PDAC患者表现出KRAS突变，其中甘氨酸取代 在密码子12的残基，如KRASG 12 D，观察到的频率很高。许多对老鼠的研究明确表明 直接抑制致癌KRAS可显著抑制肿瘤进展。尽管如此引人注目 致癌KRAS在PDAC发病机制中的功能作用的证据，直接靶向致癌KRAS， KRAS一直难以捉摸，它经常被称为“坚不可摧”。在这项拨款申请中，我们建议 探索一种新的方法，使用称为外泌体的生理纳米颗粒靶向致癌KRAS。 外来体是40-150 nm的细胞外囊泡（EV），其含有DNA、RNA和蛋白质，并且可以递送DNA、RNA和蛋白质。 它们的内容物有效地进入它们与之融合和/或进入的细胞。利用外泌体的这一独特功能， 一个研究小组在这项拨款申请中提出了一个中心假设，即“外泌体可以被 工程化以递送RNA干扰（RNAi）分子以靶向胰腺癌中的KRASG 12 D。 成功完成拟议的研究将确定外泌体是否表现出上级能力， 当与脂质体相比时，递送RNAi分子用于治疗胰腺癌。此外，在 使用多个实验系统研究这种增加的能力，该提案将进一步确定 在RNAi分子的递送中与外泌体的增强功效相关的一种或多种机制。 总的来说，该提案旨在进行深入的临床前研究，并调查 外泌体的独特作用机制可能有助于未来在患有 PDAC。